[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Ohishi Y, Oda Y, Uchiumi T, Kobayashi H, Hirakawa T, Miyamoto S, Kinukawa N, Nakano H, Kuwano M, Tsuneyoshi M: ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin Cancer Res; 2002 Dec;8(12):3767-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma.
  • PURPOSE: The purpose of this study is to attempt to characterize patients with unfavorable clinical outcome by the relative mRNA levels of ABC transporter expression in their tumor samples and to examine whether relative mRNA levels of each of the ABC transporters can be a useful predictor of progression-free survival in advanced ovarian carcinoma.
  • EXPERIMENTAL DESIGN: We examined tumor samples taken from 30 patients with primary serous papillary adenocarcinoma of the ovary for the expression of MDR1 and MRP1, MRP2, and MRP3 mRNA by using real-time reverse transcription-PCR, and we evaluated its correlation with clinical outcome.
  • All 30 patients were divided into three groups according to clinical outcome after debulking surgery and platinum-based chemotherapy: 8 patients were classified into the unfavorable group; 11 were classified into the favorable group; and 11 were classified into intermediate group.
  • In the 30 patients with serous papillary adenocarcinoma, univariate and multivariate analysis demonstrated that the high relative mRNA levels of MRP1 expression were significantly correlated with a short period of progression-free survival.
  • CONCLUSIONS: In patients with advanced ovarian serous papillary adenocarcinoma, these results suggest that patients with an unfavorable clinical outcome are characterized by increased levels of coordinated MRP1 and MRP3 mRNA expression in their tumor samples.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Papillary / genetics. Cystadenocarcinoma, Serous / genetics. Drug Resistance, Multiple. Membrane Transport Proteins. Multidrug Resistance-Associated Proteins / genetics. Ovarian Neoplasms / genetics. RNA, Messenger / metabolism
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. DNA Primers / chemistry. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Gene Expression. Humans. Immunoenzyme Techniques. Middle Aged. P-Glycoprotein / genetics. P-Glycoprotein / metabolism. Prognosis. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12473588.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Primers; 0 / Membrane Transport Proteins; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / multidrug resistance-associated protein 1; 0 / multidrug resistance-associated protein 2; 0 / multidrug resistance-associated protein 3
  •  go-up   go-down


2. Gregory-Bass RC, Olatinwo M, Xu W, Matthews R, Stiles JK, Thomas K, Liu D, Tsang B, Thompson WE: Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis. Int J Cancer; 2008 May 1;122(9):1923-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis.
  • Current approaches to the treatment of ovarian cancer are limited because of the development of resistance to chemotherapy.
  • Prohibitin (Phb1) is a possible candidate protein that contributes to development of drug resistance, which could be targeted in neoplastic cells.
  • Phb1 is a highly conserved protein that is associated with a block in the G0/G1 phase of the cell cycle and also with cell survival.
  • Our study was designed to determine the role of Phb1 in regulating cellular growth and apoptosis in ovarian cancer cells.
  • Our results showed that Phb1 content is differentially overexpressed in papillary serous ovarian carcinoma and endometrioid ovarian adenocarcinoma when compared to normal ovarian epithelium and was inversely related to Ki67 expression.
  • Immunofluorescence microscopy and Western analyses revealed that Phb1 is primarily associated with the mitochondria in ovarian cancer cells.
  • Over-expression of Phb1 by adenoviral Phb1 infection resulted in an increase in the percentage of ovarian cancer cells accumulating at G0/G1 phase of the cell cycle.
  • Treatment of ovarian cancer cells with staurosporine (STS) induced apoptosis in a time-dependent manner.
  • In contrast, silencing of Phb1 expression by adenoviral small interfering RNA (siRNA) sensitized ovarian cancer cells to STS-induce apoptosis.
  • Furthermore, silencing of the Phb1 gene expression may prove to be a valuable therapeutic approach for chemoresistant ovarian cancer by increasing sensitivity of cancer cells to apoptosis.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] EMBO J. 2000 Jun 1;19(11):2444-51 [10835343.001]
  • [Cites] Exp Gerontol. 1996 Jan-Apr;31(1-2):245-52 [8706794.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1699-706 [11245486.001]
  • [Cites] Exp Cell Res. 2001 May 1;265(2):262-73 [11302691.001]
  • [Cites] Endocrinology. 2001 Sep;142(9):4076-85 [11517187.001]
  • [Cites] Mech Ageing Dev. 2002 Feb;123(4):287-95 [11744041.001]
  • [Cites] Oncogene. 2002 Jul 4;21(29):4539-48 [12085232.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):44870-6 [12244097.001]
  • [Cites] Exp Cell Res. 2003 Feb 15;283(2):135-45 [12581734.001]
  • [Cites] Endocrinology. 2003 Apr;144(4):1496-505 [12639934.001]
  • [Cites] Cell Death Differ. 2003 Aug;10(8):870-80 [12867994.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):32091-9 [12794069.001]
  • [Cites] Oncogene. 2004 Apr 15;23(17):2996-3004 [14968116.001]
  • [Cites] EMBO J. 2004 Jun 2;23(11):2293-303 [15141164.001]
  • [Cites] Biol Reprod. 2004 Jul;71(1):282-90 [15028627.001]
  • [Cites] J Reprod Fertil. 1997 Mar;109(2):337-48 [9155744.001]
  • [Cites] Mol Endocrinol. 1999 Aug;13(8):1364-72 [10446909.001]
  • [Cites] Anat Rec. 1999 Sep 1;256(1):40-8 [10456984.001]
  • [Cites] Mol Biol Cell. 2005 Jan;16(1):248-59 [15525670.001]
  • [Cites] Trends Mol Med. 2005 Apr;11(4):192-7 [15823758.001]
  • [Cites] Nat Cell Biol. 2005 Aug;7(8):837-43 [16041367.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6325-32 [16144937.001]
  • [Cites] Curr Cancer Drug Targets. 2006 May;6(3):207-27 [16712458.001]
  • [Cites] J Biol Chem. 2006 Nov 24;281(47):36401-10 [17008324.001]
  • [Cites] Endocrinology. 2007 Jan;148(1):206-17 [17038561.001]
  • [Cites] Oncogene. 2007 Mar 15;26(12):1757-68 [16964284.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):815-9 [17429401.001]
  • [Cites] Front Biosci. 2007;12:3628-39 [17485326.001]
  • [Cites] J Biol Chem. 2007 Jul 6;282(27):19426-41 [17493932.001]
  • [Cites] Reprod Biol Endocrinol. 2003 Oct 7;1:66 [14609433.001]
  • [Cites] Proteomics. 2004 Oct;4(10):3276-87 [15378696.001]
  • [Cites] Cell. 1986 Dec 5;47(5):767-76 [3779841.001]
  • [Cites] Trends Genet. 1993 Jan;9(1):22-6 [8434413.001]
  • [Cites] J Cell Physiol. 1993 Nov;157(2):289-95 [8227162.001]
  • [Cites] Cancer Lett. 1994 Aug 15;83(1-2):201-7 [8062216.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):37101-9 [10958795.001]
  • (PMID = 18183577.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / 1 C06 RR18386; United States / NCRR NIH HHS / RR / G12 RR003034; United States / NCRR NIH HHS / RR / C06 RR018386; United States / NICHD NIH HHS / HD / R01 HD057235; United States / FIC NIH HHS / TW / R21 TW006804-02S1; United States / NCRR NIH HHS / RR / RR03034; United States / NCATS NIH HHS / TR / UL1 TR000454; United States / FIC NIH HHS / TW / R21 TW006804-01; United States / NICHD NIH HHS / HD / U54 HD041749; United States / NICHD NIH HHS / HD / U54 HD041749-01; United States / NICHD NIH HHS / HD / U54 HD41749; United States / FIC NIH HHS / TW / R21 TW006804; United States / FIC NIH HHS / TW / R21 TW006804-02
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Ki-67 Antigen; 0 / RNA, Small Interfering; 0 / Recombinant Proteins; 0 / Repressor Proteins; 0 / prohibitin; EC 3.4.22.- / Caspase 3; H88EPA0A3N / Staurosporine
  • [Other-IDs] NLM/ NIHMS350695; NLM/ PMC3272361
  •  go-up   go-down


3. Vaidya AP, Littell R, Krasner C, Duska LR: Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:267-72
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel.
  • Uterine papillary serous carcinoma (UPSC) is more aggressive than endometrioid endometrial cancer, as it often presents with advanced disease and follows a pattern of spread that resembles the serous carcinoma of the ovary.
  • Tumor registry search was used to identify all patients with UPSC from 1990 to 2003.
  • Charts were retrospectively evaluated from patients who had received at least three cycles of carboplatin and paclitaxel as first-line chemotherapy.
  • Only patients with histologically confirmed UPSC who were treated first line with carboplatin/paclitaxel chemotherapy were included.
  • Five patients were treated with consolidation radiotherapy following first-line chemotherapy.
  • Fourteen patients achieved a complete response following chemotherapy.
  • The results of Gynecologic Oncology Group protocol 122 suggest that patients with advanced endometrial cancer have an improved progression-free survival when treated primarily with chemotherapy rather than radiation therapy.
  • The results of our study show a high response rate to paclitaxel/carboplatin outpatient chemotherapy in a group of patients historically believed to have chemoresistant disease.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Endometrial Neoplasms / drug therapy. Registries
  • [MeSH-minor] Aged. Aged, 80 and over. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Remission Induction. Retrospective Studies. Treatment Outcome

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515602.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


Advertisement
4. O'Toole SA, Sheppard BL, McGuinness E, Gleeson NC, Bonnar J: Serous papillary adenocarcinomas of the ovary display heterogeneity in their response to chemotherapy. Int J Gynecol Cancer; 2001 Sep-Oct;11(5):365-71
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous papillary adenocarcinomas of the ovary display heterogeneity in their response to chemotherapy.
  • The response of ovarian serous papillary adenocarcinomas to various cytotoxic drugs was examined using the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) (MTS) cytotoxicity assay.
  • The MTS chemosensitivity assay was performed on each tumor to examine the response to cisplatin, paclitaxel, hycamtin and the combination of cisplatin and paclitaxel.
  • Ovarian adenocarcinomas of similar stage and grade displayed varying responses to the same drug.
  • A lower concentration of the drug was often as effective as the peak plasma concentration.
  • For some specimens combination therapy was more effective for inhibiting tumor growth, and for others single-agent therapy gave a better response.
  • A chemosensitivity/resistance profile is recommended before deciding on appropriate chemotherapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cystadenocarcinoma, Serous / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Cisplatin / pharmacology. Drug Therapy, Combination. Female. Humans. Neoplasm Staging. Paclitaxel / pharmacology. Topotecan / pharmacology. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11737467.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer; 2009 Jul;19(5):860-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
  • To evaluate the potential of epithelial cell adhesion molecule (Ep-CAM/TROP-1)-specific immunotherapy against epithelial ovarian carcinomas (EOCs), we have analyzed the expression of Ep-CAM at RNA and protein level in patients harboring primary, metastatic, and chemotherapy-resistant/recurrent EOC.
  • Epithelial cell adhesion molecule expression was evaluated by real-time polymerase chain reaction and immunohistochemistry in 168 fresh-frozen biopsies and paraffin-embedded tissues.
  • In addition, Ep-CAM surface expression was evaluated by flow cytometry in several freshly established ovarian carcinoma cell lines derived from patients harboring tumors resistant to chemotherapy in vivo as well as in vitro.
  • Epithelial cell adhesion molecule transcript was found significantly overexpressed in primary, metastatic, and recurrent EOC when compared with normal human ovarian surface epithelium cell lines and fresh-frozen normal ovarian tissue (P < 0.001).
  • Similarly, by immunohistochemistry, Ep-CAM protein expression was found significantly higher in primary, metastatic, and recurrent EOC when compared with normal ovarian tissues.
  • Of interest, metastatic/recurrent tumors were found to express significantly higher levels of Ep-CAM protein when compared with primary ovarian carcinomas (P < 0.001).
  • Finally, a high surface expression of Ep-CAM was found in 100% (5/5) of the chemotherapy-resistant ovarian carcinoma cell lines studied by flow cytometry.
  • These results demonstrate high Ep-CAM overexpression in ovarian carcinoma, especially in metastatic and recurrent/chemotherapy-resistant ovarian disease.
  • The lack of Ep-CAM expression on the chelomic epithelium in the peritoneal cavity, combined with the recent development of fully human monoclonal antibodies against this surface molecule, suggest Ep-CAM as a promising target for antibody-mediated therapies in ovarian carcinoma patients harboring tumors refractory to standard treatment modalities.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Adhesion Molecules / metabolism. Drug Resistance, Neoplasm. Neoplasm Recurrence, Local / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Blotting, Western. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / secondary. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / secondary. Female. Flow Cytometry. Humans. Immunoenzyme Techniques. Middle Aged. Organoplatinum Compounds / administration & dosage. Ovary / metabolism. Ovary / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574774.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Organoplatinum Compounds; 0 / RNA, Messenger
  •  go-up   go-down


6. Kelly MG, O'Malley D, Hui P, McAlpine J, Dziura J, Rutherford TJ, Azodi M, Chambers SK, Schwartz PE: Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gynecol Oncol; 2004 Dec;95(3):469-73
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.
  • OBJECTIVE: The coexistence of minimal uterine disease and extrauterine metastases is common in patients with uterine papillary serous carcinoma (UPSC).
  • The purpose of this study was to evaluate different therapeutic options in surgically staged patients.
  • Additionally, 11 of these 51 patients (21%) were diagnosed with two cancers: a stage IA UPSC and concomitant advanced stage serous cancer of the ovary, fallopian tube, or peritoneum.
  • Stage IA patients with no cancer in the hysterectomy specimen (defined as no residual uterine disease) had no recurrences (n = 10) regardless of treatment.
  • There was a trend toward increased survival in stage IA patients with residual uterine disease who were treated with chemoradiation (concomitant vaginal brachytherapy and platinum-based chemotherapy).
  • All patients with advanced stage UPSC (stage IIIC or IV or two primary cancers) did poorly regardless of treatment.
  • More effective treatment needs to be identified for advanced stage UPSC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Papillary / therapy. Cystadenocarcinoma, Serous / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Brachytherapy. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15581948.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin
  •  go-up   go-down


7. Laurent I, Uzan C, Gouy S, Pautier P, Duvillard P, Morice P: Results after conservative treatment of serous borderline tumors of the ovary with a micropapillary pattern. Ann Surg Oncol; 2008 Dec;15(12):3561-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results after conservative treatment of serous borderline tumors of the ovary with a micropapillary pattern.
  • OBJECTIVE: The aim of this study was to assess the outcomes of patients treated conservatively for a serous borderline ovarian tumor with micropapillary patterns (SBOT-MP).
  • METHODS: Retrospective study collecting cases of conservative treatment of SBOT-MP.
  • Eight patients underwent a unilateral salpingo-oophorectomy with a contralateral cystectomy, three a unilateral salpingo-oophorectomy, two a cystectomy, and two a bilateral cystectomy.
  • Four patients had stromal microinvasion associated with MP at histological examination of the ovarian tumor.
  • One patient received adjuvant chemotherapy.
  • RESULTS: After a median interval of 63 months (range, 18-120 months), 11 recurrences were observed: six of them exclusively on the ovary, three exclusively on the peritoneum (invasive peritoneal disease in one), and two on the ovary and peritoneum.
  • CONCLUSION: This study demonstrates that spontaneous pregnancies can be achieved after conservative treatment of SBOT-MP.
  • Nevertheless, as 2/3 of patients had bilateral ovarian involvement at the time of initial management, the recurrence rate is high.
  • However, making definitive conclusions about the safety of conservative surgery is limited by the small sample size.
  • [MeSH-major] Cystadenocarcinoma, Papillary / surgery. Cystadenocarcinoma, Serous / surgery. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Neoplasm Invasiveness. Neoplasm Staging. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery. Prognosis. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18820973.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Jaishuen A, Berrios-Rivera JP, Sirisabya N, Zheng HG, Li Y, Kavanagh JJ: Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary. Int J Gynecol Cancer; 2008 Mar-Apr;18(2):379-83
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary.
  • Bevacizumab (BVC) is currently used in recurrent ovarian cancer and as part of the initial treatment for ovarian cancer.
  • Arthritis had never been addressed in patients who received BVC treatment.
  • A 59-year-old female with recurrent ovarian cancer received multiple hormonal and cytotoxic regimens for 5 years and then developed erosive osteoarthritis of the hands secondary to BVC and paclitaxel.
  • This effect was confirmed by a significant improvement in her symptoms and signs, after treatment was discontinued.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cystadenocarcinoma, Serous / drug therapy. Neoplasm Recurrence, Local / drug therapy. Osteoarthritis / chemically induced. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Osteoarthritis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624988.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC: Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol; 2006 Aug;108(2):361-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
  • OBJECTIVE: To analyze the clinical behavior of patients with stage II-IV low-grade serous carcinoma of the ovary seen at our institution who underwent primary surgery followed by platinum-based chemotherapy.
  • METHODS: Patients with stage II-IV low-grade serous carcinoma of the ovary from 1978 to 2003 were identified using existing databases.
  • Response rate to platinum-based chemotherapy in 10 evaluable patients (15% of patients with gross residual disease) was 80%, and 42 patients underwent second-look surgery: microscopically negative findings, 2 (5%); microscopically positive disease, 13 (33%); macroscopically positive disease, 24 (62%); and insufficient information, 3 (7%).
  • Median progression-free survival and overall survival times were 19.5 and 81.8 months.
  • Persistent disease after primary chemotherapy was the only factor associated with shorter overall survival time (hazard ratio 3.46, 95% confidence interval 2.00-5.97, P<.001).
  • CONCLUSION: Metastatic low-grade serous carcinoma of the ovary is characterized by young age at diagnosis and prolonged overall survival.
  • [MeSH-major] Cystadenocarcinoma, Papillary / mortality. Cystadenocarcinoma, Papillary / therapy. Ovarian Neoplasms / mortality. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Survival Analysis. Texas / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16880307.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Wu M, Shen K, Lang J, Huang R, Huang H, Pan L: [Transitional cell carcinoma of the ovary: one kind of uncommon type of ovarian epithelial carcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2002 Dec;37(12):733-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transitional cell carcinoma of the ovary: one kind of uncommon type of ovarian epithelial carcinoma].
  • OBJECTIVE: To evaluated clinico-biologic behavior, prognosis and relative prognostic factors of transitional cell carcinoma of the ovary.
  • METHODS: The clinical records of 58 patients with transitional cell carcinoma of the ovary, who received treatment in the department of Obstetrics and Gynecology, Peking Union Medical College Hospital in 20 years, were reviewed retrospectively.
  • 31% of them had bilateral ovary involvement, and the median level of CA(125) was (687 +/- 365) U/L.
  • Different courses of chemotherapy were given to all patients.
  • The Cox hazards regression model was used to analyze the possible prognostic factors and revealed that tumor residuals (P < 0.01), preoperative level of CA(125) (P < 0.01), bilateral ovary involvement (P < 0.05) and lymph node metastasis (P < 0.05) were the most important prognostic factors.
  • CONCLUSIONS: Transitional cell carcinoma of ovary is an uncommon type of ovarian cancer.
  • It usually behaves better prognosis when compared with papillary serous cystadenocarcinoma of the ovary.
  • [MeSH-major] Carcinoma, Transitional Cell / mortality. Ovarian Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12622917.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Bing Z, Adegboyega PA: Metastasis of small cell carcinoma of lung into an ovarian mucinous neoplasm: immunohistochemistry as a useful ancillary technique for diagnosis and classification of rare tumors. Appl Immunohistochem Mol Morphol; 2005 Mar;13(1):104-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of small cell carcinoma of lung into an ovarian mucinous neoplasm: immunohistochemistry as a useful ancillary technique for diagnosis and classification of rare tumors.
  • The authors report the first case of ovarian mucinous adenocarcinoma with metastasis from a synchronous small cell neuroendocrine carcinoma of the lung.
  • The patient received 3 cycles of chemotherapy with carboplatin and subsequently underwent a supracervical hysterectomy and bilateral salpingo-oophorectomy.
  • A large, multiloculated cystic mass was found arising from the right ovary.
  • Microscopic examination disclosed a mucinous neoplasm with both mucinous cystadenoma and mucinous papillary adenocarcinoma components.
  • A microscopic focus of cells with "atypical" cytomorphologic features was detected within the mucinous neoplasm.

  • Genetic Alliance. consumer health - Ovarian small cell carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15722802.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 1.11.1.- / Peroxidases
  •  go-up   go-down


12. Qian J, Shi Y, Chen X: [Clinical analysis of 25 cases of malignant transformation of endometriosis of the ovary]. Zhonghua Fu Chan Ke Za Zhi; 2000 Nov;35(11):667-9
MedlinePlus Health Information. consumer health - Ovarian Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 25 cases of malignant transformation of endometriosis of the ovary].
  • OBJECTIVE: To study clinicopathologic characteristics, treatment and prognostic factors of malignant transformation of endometriosis of the ovary.
  • METHODS: From 1981 to 1999, a total of 25 patients with malignant transformation of endometriosis of the ovary were retrospectively analyzed.
  • Histological type: of the 25 cases, 14 were endometrioid carcinomas, 2 were clear-cell carcinomas, 2 were adenoacanthoma, 1 was serous papillary adenocarcinomas, 6 were mixed epithelium tumor of ovary.
  • Radical tumor resection combined with chemotherapy is the main therapeutic approach for malignant transformation of endometriosis of the ovary.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Endometriosis / pathology. Ovarian Diseases / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11218895.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Pusiol T, Zorzi MG, Morichetti D, Piscioli I, Scialpi M: Peritoneal Malignant Psammomatous Mesothelioma. World J Oncol; 2010 Aug;1(4):179-181

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Psammoma bodies (PBs) are observed most commonly in papillary thyroid carcinoma, meningioma, and papillary serous cystadenocarcinoma of the ovary.
  • Contrast enhanced computed tomography showed fluid diffuse in peritoneal recesses, thick septa with micronodules in the greater omentum and adjacent enhancement of the thickened peritoneum.
  • The peritoneal biopsy revealed a superficial papillary growth of malignant epithelial-like cells with diffuse involvement of submesothelial tissues.
  • The patient was treated with chemotherapy (gemcitabine, vinorelbine, cisplatin).
  • PBs may represent an active biologic process ultimately leading to degeneration/death of tumor cells and retardation of growth of the neoplasm.
  • It may also serve as a barrier against the spread of tumor.
  • The behavior of serous psammocarcinoma is more closely similar to borderline serous tumor than to serous carcinoma.
  • Further studies are necessary to establish if massive deposition of PBs may define a new variant of psammomatous malignant mesothelioma with a favorable impact to the prognosis of usual psammomatous malignant mesothelioma, as well as in serous psammocarcinoma of the peritoneum.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 2005 Jan-Feb;91(1):1-5 [15849996.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):285-94 [10680897.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):372-80 [15891998.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):816-23 [10843283.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):292-6 [2295052.001]
  • [Cites] Histopathology. 2006 Feb;48(3):223-32 [16430468.001]
  • [Cites] Arch Gynecol Obstet. 2009 Jun;279(6):931-6 [18982336.001]
  • [Cites] Acta Med Port. 2002 Sep-Oct;15(5):383-6 [12645223.001]
  • [Cites] Histopathology. 1997 May;30(5):403-18 [9181361.001]
  • [Cites] Diagn Cytopathol. 2009 Jul;37(7):534-41 [19373908.001]
  • (PMID = 29147203.001).
  • [ISSN] 1920-454X
  • [Journal-full-title] World journal of oncology
  • [ISO-abbreviation] World J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Malignant mesothelioma / Psammoma bodies / Psammomatous malignant mesothelioma
  •  go-up   go-down


14. Veroni S, Terzopoulou K, Anagnostopoulou I, Vassilakaki T, Grammatoglou X, Rammou R: Extraovarian peritoneal serous papillary carcinoma: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):879-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraovarian peritoneal serous papillary carcinoma: a case report.
  • BACKGROUND: Extraovarian peritoneal serous papillary carcinoma (EPSPC) is a rare cancer closely related to ovarian carcinoma and characterized by abdominal carcinomatosis without an identifiable abdominal primary tumor.
  • CONCLUSION: The combination of cytology, histology, immunohistochemistry and clinical data is a reliable method for the preoperative diagnosis of EPSPC, allowing prompt chemotherapy as surgery may not be indicated in most cases.
  • [MeSH-major] Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Ovary / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Proteins / metabolism. Vacuoles / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053561.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


15. Möbus VJ, Gerharz CD, Weikel W, Merk O, Dreher L, Kreienberg R, Moll R: Characterization of a human carcinosarcoma cell line of the ovary established after in vivo change of histologic differentiation. Gynecol Oncol; 2001 Dec;83(3):523-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of a human carcinosarcoma cell line of the ovary established after in vivo change of histologic differentiation.
  • Most ovarian cancer cell lines described are serous cystadenocarcinomas or poorly differentiated adenocarcinomas.
  • The establishment of ovarian cancer cell lines with rare histologic differentiation is especially of interest.
  • We describe the establishment of a carcinosarcoma cell line of the ovary after in vivo selection.
  • METHODS: The cell line OV-MZ-22 was established from a solid tumor mass in the upper abdomen.
  • At the time of establishment, the patient underwent secondary debulking and was pretreated with six cycles of cis-platinum/epirubicin/cyclophosphamide.
  • RESULTS: The first histologic report of the patient described a papillary cystadenocarcinoma, which changed to a carcinosarcoma with predominantly sarcomatous differentiation at secondary debulking.
  • This cell line is aneuploid and shows no expression of the tumor-associated antigens CA-125 and CEA, but an overexpression of MDR-1, lung resistance protein, p53, and topoisomerase I and II, but not of multidrug-resistance-associated protein.
  • The histologic and immunocytochemical comparison of the primary and the relapsed tumor proved evidence of an in vivo change of differentiation from predominantly papillary cystadenocarcinoma to carcinosarcoma.
  • The differentiation phenotype of OV-MZ-22 cells is that of smooth-muscle cells.
  • CONCLUSION: The change of histologic differentiation was apparently due to a selection process caused by platinum-containing chemotherapy.
  • [MeSH-major] Carcinosarcoma / pathology. Ovarian Neoplasms / pathology. Tumor Cells, Cultured
  • [MeSH-minor] Actins / biosynthesis. Animals. Cell Differentiation. Cystadenocarcinoma, Papillary / genetics. Cystadenocarcinoma, Papillary / metabolism. Cystadenocarcinoma, Papillary / pathology. DNA, Neoplasm / analysis. DNA, Neoplasm / genetics. Female. Humans. Intermediate Filament Proteins / biosynthesis. Karyotyping. Keratins / biosynthesis. Mice. Mice, Nude. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Transplantation


16. Li Y, Cui H, Chang XH, Feng J, Fu TY, Feng YJ, Wei LH: [Establishment and comparison of two intraperitoneally transplanted human ovarian carcinoma models with immune reconstitution in severe combined immunodeficient mice]. Ai Zheng; 2004 Feb;23(2):160-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Establishment and comparison of two intraperitoneally transplanted human ovarian carcinoma models with immune reconstitution in severe combined immunodeficient mice].
  • BACKGROUND & OBJECTIVE: Ovarian carcinoma is leading cause of death in gynecologic malignancies.
  • The survival rate cannot be improved after routine surgery, chemotherapy, and radiotherapy.
  • Therefore biotherapy becomes the fourth treatment pattern for ovarian carcinoma.
  • Adequate experimental models for the development of biologic therapeutic strategies are needed.
  • Our purpose was to establish and compare two intraperitoneally transplanted human ovarian carcinoma models with human immune reconstitution in severe combined immunodeficient (SCID) mice.
  • METHODS: Six and ten C.B17/SCID mice were intraperitoneally injected with human ovarian adenocarcinoma SKOV3 and SKOV3.ip1 cells, respectively.
  • The latent periods of tumor growth were 20-41 days and 22-30 days, respectively (P >0.05).
  • While the mean survival time were 50-78 days and 32-43 days, respectively (P< 0.0001).
  • 83.3% (5/6) of the mice injected with ascites of the mice in SKOV3.ip1 group successfully formed new tumor mass and ascites.
  • Histological results showed the tumors of the two groups remained the characteristics of serous papillary adenocarcinoma of human ovary, and immunohistochemistry staining showed the ovarian associated antigen OC166-9 were both positive.
  • CONCLUSION: The two intraperitoneally transplanted human ovarian carcinoma models had been established in human PBL reconstituted SCID mice.
  • The SKOV3.ip1 model may be an ideal animal model for biotherapy research of ovarian carcinoma as it simulates the intraperitoneally disseminating behavior of human ovarian carcinoma in the patients with immune function, and it took relatively shorter time to be established.
  • [MeSH-major] Disease Models, Animal. Ovarian Neoplasms / immunology
  • [MeSH-minor] Animals. Female. Humans. Immunoglobulin G / blood. Immunohistochemistry. Mice. Mice, SCID. Neoplasm Transplantation. Transplantation, Heterologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14960235.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunoglobulin G
  •  go-up   go-down


17. Markaki S, Protopapas A, Milingos S, Lazaris D, Antsaklis A, Michalas S: Primary malignant mesothelioma of the peritoneum: a clinical and immunohistochemical study. Gynecol Oncol; 2005 Mar;96(3):860-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differential diagnosis between this rare tumor and both serous papillary carcinoma of the peritoneum and ovary can be problematic.
  • CASE: A 54-year-old woman presented to our institution with a 4-month history of dull epigastric pain and increased abdominal girth.
  • Exploratory laparotomy revealed the presence of extensive intraperitoneal dissemination of a malignant neoplasm without a recognizable primary site.
  • This was confirmed with a panel of immunohistochemical markers.
  • The patient despite having a complete response after adjuvant chemotherapy died 18 months after primary surgery.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721439.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Culton LK, Deavers MT, Silva EG, Liu J, Malpica A: Endometrioid carcinoma simultaneously involving the uterus and the fallopian tube: a clinicopathologic study of 13 cases. Am J Surg Pathol; 2006 Jul;30(7):844-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the simultaneous presentation of endometrial and ovarian carcinomas of the endometrioid type is well described, little is known about a similar phenomenon involving the endometrium and fallopian tube (FT).
  • In 2 cases, there were also small areas of other histologic types, papillary serous carcinoma (1 case), and papillary endometrial carcinoma of intermediate grade (another case).
  • Seven of these tumors were located in the distal/fimbriated end of the FT.
  • In 4 cases, there was also an endometrioid carcinoma involving the ovary, all of them with an intact ovarian capsule.
  • Patients were treated as follows: total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH/BSO) (4), TAH/BSO/chemotherapy (chemo) (4), TAH/BSO/radiation (3), and TAH/BSO/chemo/radiation (2).
  • The FT carcinoma is usually unilateral and located at the distal end of the tube.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Fallopian Tubes / pathology. Fallopian Tubes / surgery. Female. Humans. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16819326.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Kuscu E, Oktem M, Haberal A, Erkanli S, Bilezikci B, Demirhan B: Management of advanced-stage primary carcinoma of the fallopian tube: case report and literature review. Eur J Gynaecol Oncol; 2003;24(6):557-60
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TVS demonstrated a 35 x 25 mm heterogeneous mass that was not clearly separated from the left ovary, and another 31 x 14 mm cystic septated lesion in the left ovary region.
  • Laparotomy revealed left hydrosalpinx and a papillary-fimbrial mass.
  • The definitive histopathological diagnosis was primary serous adenocarcinoma of the fallopian tube with six of 25 lymph node biopsies showing metastasis.
  • Six cycles of paclitaxel (175 mg/m2) plus cisplatin (75 mg/m2) combinatin chemotherapy were administered with 3-week intervals between cycles.
  • At the time of writing 12 months after the second-look laparotomy, she was still disease-free.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta, Thoracic. Appendectomy. Cisplatin / administration & dosage. Diagnosis, Differential. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Lymph Nodes / surgery. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Omentum / surgery. Ovariectomy. Paclitaxel / administration & dosage. Second-Look Surgery

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14658603.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 40
  •  go-up   go-down






Advertisement